查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1834172

藥物釋放型球囊市場（按應用、藥物類型、最終用戶、產品類型和分銷管道）—全球預測 2025-2032

Drug Eluting Balloon Market by Application, Drug Type, End User, Product Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年藥物釋放型球囊市場將成長至 36.6 億美元，複合年成長率為 16.24%。

主要市場統計數據
基準年2024年 10.9億美元
預計2025年 12.7億美元
預測年份：2032年 36.6億美元
複合年成長率（%） 16.24%

全面說明藥物釋放型球囊的動態，並重點介紹當前醫療環境中的臨床前景、設備創新和商業性壓力

隨著器械創新者、介入專家和支付方重新評估血管疾病臨床治療路徑，藥物釋放型球囊領域正迎來曲折點。這一趨勢融合了加速的技術進步、更嚴格的監管審查以及不斷發展的醫療經濟，所有這些對相關人員都至關重要。在此背景下，藥物釋放型球囊因其無需留下永久植入物即可進行抗增殖治療的潛力，正重新引起人們的注意。

臨床應用正受到以下因素的影響：需要解決不同類型的冠狀動脈和周邊病變，並填補有關長期療效和安全性訊號的現有證據空白。同時，製造商正在改進藥物輸送系統、輔料和下游物流，以提高藥物傳輸效率，最大限度地降低栓塞風險，並簡化手術流程。這些漸進式改進正在創造差異化的價值提案，尤其是在避免使用永久性金屬支架具有臨床優勢的病變亞群中。

從商業性角度來看，採購商和醫院正在評估整體手術成本、長期器械相關併發症的潛在減少量以及對醫療轉型的影響。付款人和醫療採購團隊要求臨床價值與報銷之間緊密結合，因此公司必須提供清晰的比較效益證據。這種採用為深入研究轉型轉變、資費影響、細分動態、區域差異、競爭定位以及後續分析的實用建議奠定了基礎。

塗層化學、臨床試驗設計和臨床實踐的進步如何同時改變藥物釋放型球囊的患者選擇和銷售管道

隨著技術、臨床證據生成和醫療服務模式的融合，藥物釋放型球囊領域正在經歷一場變革。技術進步的重點是最佳化塗層化學成分、賦形劑以及球囊表面工程，以增強藥物的保留和向血管壁的均勻輸送。這些技術進步，加上輸送導管設計的不斷改進，以適應曲折和遠端入路，正在擴大球囊治療的適應病變範圍。

同時，臨床試驗架構正轉向頭對頭比較研究，強調以患者為中心的終點，例如生活品質、再灌注需求以及周邊介入治療中的肢體挽救。來自註冊研究和上市後監測的真實世界證據也被納入其中，以補充隨機數據，支持對細微適應症和亞群的分析。因此，分層證據正在指導冠狀動脈應用（包括新發病變和支架內血管再阻塞）以及周邊應用（區分膝下和股膕動脈區域）的應用。

市場管道和醫療保健環境正在根據不斷變化的經濟狀況和手術複雜性進行調整。門診手術中心正在提升其支持微創手術的能力，從而創造機會將某些手術從住院醫院轉移出去。同時，設備開發商和分銷合作夥伴之間的策略聯盟正在加速產品覆蓋範圍，同時使製造商能夠專注於臨床開發和監管策略。總而言之，這些轉變正在重塑競爭優勢，提高臨床檢驗的標準，並強調將設備性能與證據生成和報銷支援相結合的綜合提案主張。

預計 2025 年的關稅壓力將迫使製造商最佳化供應鏈和籌資策略，同時保留臨床價值提案

美國將於2025年加徵關稅，這對藥物釋放型球囊製造商和採購商而言，是關鍵的商業性考量因素，將影響其採購、定價和供應鏈韌性。進口零件和成品關稅導致成本增加，這促使製造商重新評估其全球製造地、供應商合約條款和對沖策略，以減輕利潤壓縮的影響。同時，醫院、診所和門診手術中心的採購團隊正在重新評估其供應商選擇標準，並將潛在的價格波動和總到岸成本納入考量。

鑑於關稅的影響，一些公司正在加速關鍵製造流程的在地化，或在免稅地區尋找替代供應商，以保持成本競爭力。另一些公司則正在重新審視其銷售合約和服務模式，以平衡營運成本限制和庫存。這些商業決策不僅受制於直接的成本影響，也受到智慧財產權保護、監管協調和供應商風險集中等長期策略考量。

根據產品類型及其供應鏈架構，臨床醫生和管理人員可能會看到各種結果。對於依賴商品化組件的傳統球囊，利潤壓力可能反映在價格談判和轉向主導的採購模式上。對於技術含量高且具有專有塗層的特種球囊，製造商可能會承擔部分關稅成本以保護其市場地位，同時試圖透過展示臨床效用來證明溢價的合理性。關稅驅動的動態凸顯了供應鏈透明度、自適應籌資策略以及與付款人和採購相關人員積極互動的重要性，以使價值預期與不斷變化的成本結構保持一致。

策略性細分的必要性顯示了應用、藥物化學、護理環境、產品差異化和通路選擇如何決定採取路徑。

細分洞察揭示了不同應用領域、藥物類型、最終用戶、產品類型和分銷管道之間存在的細微機會和限制因素，需要製定有針對性的策略，而非一刀切。在冠狀動脈領域，臨床醫師在選擇球囊治療方案時會區分新生血管性病變和支架內再血管再阻塞；而在周邊動脈領域，由於病變形態和臨床目標的顯著差異，臨床醫師會將膝下段和股膕動脈段區分開來。這些臨床細分領域決定了器材設計需求、證據需求和術後追蹤路徑。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用新型無聚合物藥物塗層減少藥物釋放型球囊手術中的晚期不利事件
  • Sirolimus洗脫球囊技術擴大了周邊動脈疾病患者的治療選擇
  • 透過將血管內影像導引系統與藥物釋放型球囊治療方法結合，準確評估病變
  • 醫療設備製造商與製藥公司建立策略夥伴關係，最佳化球囊藥物輸送
  • 增加對微孔技術的投資，以提高球囊血管成形術干預期間的局部藥物傳輸效率
  • 更重視衛生經濟學和報銷策略，以改善藥物釋放型球囊設備的市場進入
  • 由於周邊動脈疾病發病率上升和醫療基礎設施改善，亞太市場將快速成長

第6章 2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章藥物釋放型球囊市場（依應用）

  • 冠狀動脈疾病
    • 新的病變
    • 支架內血管再阻塞
  • 周邊動脈疾病
    • 膝蓋以下
    • 股膕肌

第9章藥物釋放型球囊市場（依藥物類型）

  • 紫杉醇塗層
  • Sirolimus塗層

第 10 章藥物釋放型球囊市場（依最終用戶）

  • 門診手術中心
  • 診所
  • 醫院

第11章藥物釋放型球囊市場（依產品類型）

  • 常規氣球
  • 特殊氣球

第12章藥物釋放型球囊市場（依通路）

  • 直接地
  • 批發商

第13章藥物釋放型球囊市場（依地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章藥物釋放型球囊市場：依類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章藥物釋放型球囊市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Medtronic plc
    • Boston Scientific Corporation
    • B. Braun SE
    • Koninklijke Philips NV
    • Becton Dickinson and Company
    • Terumo Corporation
    • MicroPort Scientific Corporation
    • Cook Medical LLC
    • Elixir Medical Corporation
    • Concept Medical Research Private Limited
Product Code: MRR-4348D129FA8E

The Drug Eluting Balloon Market is projected to grow by USD 3.66 billion at a CAGR of 16.24% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.09 billion
Estimated Year [2025] USD 1.27 billion
Forecast Year [2032] USD 3.66 billion
CAGR (%) 16.24%

A comprehensive orientation to drug eluting balloon dynamics that situates clinical promise, device innovation, and commercial pressures in the current healthcare environment

The drug eluting balloon landscape is at an inflection point as device innovators, interventionalists, and payers reassess clinical pathways for vascular disease management. This introduction frames the essential context for stakeholders who must navigate accelerating technological refinement, heightened regulatory scrutiny, and evolving care-site economics. Against this backdrop, drug eluting balloons are attracting renewed attention for their potential to deliver antiproliferative therapy without leaving a permanent implant, which has important implications for patient management strategies and follow-up care patterns.

Clinical adoption is being shaped by the need to address heterogeneous lesion types across coronary and peripheral territories, and by the imperative to close evidence gaps that persist around long-term outcomes and safety signals. At the same time, manufacturers are refining delivery systems, excipients, and downstream logistics to improve drug transfer efficiency, minimize embolic risk, and streamline procedural workflows. These incremental improvements are creating differentiated value propositions, particularly for lesion subsets where avoiding permanent metallic scaffolds is clinically advantageous.

From a commercial perspective, purchasers and hospitals are evaluating total procedure cost, potential reductions in long-term device-related complications, and implications for care setting migration. As payers and institutional procurement teams demand tighter alignment between clinical value and reimbursement, companies must articulate clear evidence of comparative benefits. This introduction sets the stage for a deeper examination of transformative shifts, tariff influences, segmentation dynamics, regional variance, competitive positioning, and pragmatic recommendations that follow in this analysis.

How simultaneous advances in coating chemistry, clinical trial design, and care-site migration are reshaping patient selection and commercial pathways for drug eluting balloons

The drug eluting balloon domain is experiencing transformative shifts driven by converging forces in technology, clinical evidence generation, and care delivery models. Technological evolution centers on coating chemistries, excipient optimization, and balloon surface engineering to enhance drug retention and uniform transfer to the vessel wall. These technical refinements are accompanied by iterative improvements in delivery catheter design to address tortuosity and distal access, which together broaden the range of lesions amenable to balloon-based therapy.

Concurrently, clinical trial architecture is shifting toward head-to-head comparative studies that emphasize patient-centered endpoints such as quality of life, need for repeat revascularization, and limb salvage in peripheral interventions. The community is also incorporating real-world evidence from registries and post-market studies to complement randomized data, thereby supporting nuanced indications and subpopulation analyses. As a result, adoption is being guided by evidence stratified across coronary applications including de novo lesions and in-stent restenosis, as well as peripheral applications that differentiate below knee and femoropopliteal territories.

Market channels and care settings are adjusting in response to evolving economics and procedural complexity. Ambulatory surgical centers are increasingly capable of supporting minimally invasive interventions, creating opportunities to shift certain procedures out of inpatient hospital settings. At the same time, strategic partnerships between device developers and distribution partners are accelerating product reach while allowing manufacturers to focus on clinical development and regulatory strategy. Collectively, these shifts are reconfiguring competitive advantage, raising the bar for clinical validation, and emphasizing integrated value propositions that combine device performance with evidence generation and reimbursement support.

Projected tariff pressures in 2025 compelling manufacturers to optimize supply chains and procurement strategies while protecting clinical value propositions

The imposition of United States tariffs scheduled for implementation in 2025 introduces a material commercial consideration for manufacturers and purchasers of drug eluting balloons, with implications across sourcing, pricing, and supply chain resilience. Tariff-driven cost increases for imported components or finished devices are prompting manufacturers to re-evaluate global manufacturing footprints, contract terms with suppliers, and hedging strategies that can mitigate margin compression. In parallel, procurement teams within hospitals, clinics, and ambulatory surgical centers are reassessing vendor selection criteria to account for potential price volatility and total landed cost.

In anticipation of tariff effects, some companies are accelerating localization of critical manufacturing steps or qualifying alternative suppliers in tariff-exempt jurisdictions to preserve cost competitiveness. Others are revisiting distribution agreements and service models to balance inventory positioning against working capital constraints. These operational decisions are informed not only by immediate cost impacts but also by longer-term strategic considerations such as intellectual property protection, regulatory harmonization, and supplier risk concentration.

Clinicians and administrators will likely see differentiated outcomes depending on product type and supply chain architecture. For conventional balloons that rely on commoditized components, margin pressure may translate into pricing negotiations or shifts toward distributor-led procurement models. For specialty balloons with higher technical content and proprietary coatings, manufacturers may absorb a degree of tariff-induced cost to protect market positioning, while seeking to justify premium pricing through demonstrated clinical benefit. Ultimately, tariff-driven dynamics underscore the importance of supply chain transparency, adaptable sourcing strategies, and proactive engagement with payers and procurement stakeholders to align expected value with evolving cost structures.

Strategic segmentation imperatives demonstrating how distinct application, drug chemistry, care setting, product differentiation, and channel choices determine adoption pathways

Segmentation insights reveal nuanced opportunities and constraints across application, drug type, end user, product type, and distribution channel that demand targeted strategies rather than one-size-fits-all approaches. Based on application, adoption patterns diverge between coronary artery disease and peripheral artery disease; within coronary practice, clinicians distinguish between de novo lesions and in-stent restenosis when selecting balloon-based therapy, while peripheral specialists separate decisions for below knee and femoropopliteal segments because lesion morphology and clinical objectives differ markedly. These clinical subsegments shape device design requirements, evidence needs, and post-procedural follow-up pathways.

Based on drug type, the dichotomy between paclitaxel-coated and sirolimus-coated balloons continues to influence investment priorities and clinician perception. Paclitaxel-based platforms remain notable for historical adoption in specific peripheral indications and for established transfer kinetics, while sirolimus-coated systems are gaining traction due to the drug's antiproliferative profile and perceived potential for improved safety in select settings. Manufacturers must therefore align clinical programs and messaging with the pharmacologic attributes and regulatory expectations associated with each drug type.

Based on end user, market dynamics vary across ambulatory surgical centers, clinics, and hospitals, as each care setting has distinct infrastructure, procedural throughput, and purchasing protocols. Ambulatory surgical centers may prioritize devices that streamline workflow and shorten recovery, clinics may focus on devices enabling less invasive outpatient interventions, and hospitals typically evaluate devices within broader service-line economics and capital planning frameworks. Concomitantly, based on product type, conventional balloons and specialty balloons occupy different value tiers; specialty balloons command attention where lesion complexity or adjunctive technology warrants differentiated performance, while conventional balloons remain relevant where cost sensitivity and familiarity drive selection.

Based on distribution channel, strategic choices between direct sales and distributor partnerships affect market access, customer service models, and data feedback loops. Direct engagement can support closer clinical collaboration and tailored training, whereas distributor networks can accelerate regional penetration and reduce operational overhead. Taken together, this segmentation architecture underscores that successful commercialization demands tightly aligned clinical evidence, product differentiation, and distribution strategies that reflect the specific needs of the clinical subsegments and care settings targeted.

Comparative regional dynamics and market access realities illustrating how regulatory nuance, reimbursement policy, and clinical practice shape adoption across global markets

Regional dynamics for drug eluting balloons are shaped by heterogeneous regulatory environments, reimbursement frameworks, and clinical practice patterns across Americas, Europe, Middle East & Africa, and Asia-Pacific, each of which presents distinct opportunities and commercialization challenges. In the Americas, clinical practice emphasizes outcome-driven device selection and robust post-market surveillance, while procurement decision-making tends to weigh long-term value against upfront cost, influencing how manufacturers position evidence and pricing models.

Within Europe, Middle East & Africa, regulatory harmonization efforts coexist with national-level reimbursement policies that create a mosaic of access pathways; manufacturers must therefore calibrate launch sequencing and medical affairs engagement to local HTA and hospital purchasing processes. In the Asia-Pacific region, diverse market maturity and rapid infrastructure investment in urban centers create opportunities for both flagship product launches and localized manufacturing, though region-specific clinical preferences and regulatory timelines require tailored market entry strategies. Transitional considerations across regions include the growing importance of registry data, cross-border clinical collaborations, and the potential for regional centers of excellence to influence wider adoption patterns.

Across all geographies, supply chain robustness and tariff exposure remain central concerns for stakeholders. The interplay between regional reimbursement rules and clinical evidence requirements will continue to shape where and how quickly new drug eluting balloon technologies achieve traction, making strategic regional prioritization a critical component of commercialization planning.

Competitive ecosystem overview emphasizing clinical differentiation, manufacturing partnerships, and evidence-driven commercial execution as determinants of leadership

Competitive dynamics in the drug eluting balloon space reflect a mix of established medical device companies, specialized interventional device innovators, and strategic collaborations that combine clinical expertise with manufacturing scale. Established players leverage broad commercial footprints and integrated salesforces to support hospital adoption, while niche innovators focus on differentiated coating technologies, excipient systems, and catheter performance to win specific lesion segments or care settings. Partnerships between clinical opinion leaders and device developers are becoming more prevalent as a route to accelerate evidence generation and to refine procedural technique training.

Investment in clinical development is increasingly a differentiator; companies that can produce robust, transparent outcome data and real-world registry evidence gain credibility with both clinicians and payers. At the same time, regulatory approvals and post-market surveillance commitments remain a critical determinant of competitive positioning, particularly where historical safety questions or device-specific concerns require active risk mitigation. Mergers, acquisitions, and licensing arrangements are shaping the landscape by consolidating intellectual property and bolstering distribution channels, while contract manufacturers and specialized coating houses play an essential role in scaling production for newer drug formulations.

Commercial execution also hinges on service-oriented capabilities such as procedure training, reimbursement support, and patient selection tools that reduce the friction of adoption. Ultimately, market leadership will favor organizations that combine scientific differentiation with operational excellence in supply chain, clinical evidence generation, and stakeholder engagement.

Actionable strategic priorities for manufacturers and stakeholders to align clinical evidence, supply chain resilience, and tailored commercial models for scalable adoption

Industry leaders should pursue an integrated strategy that aligns product development, clinical evidence, and commercial execution to accelerate sustainable adoption. Prioritize investments in head-to-head and real-world studies that address high-impact clinical endpoints-particularly within the differentiated application subsegments of de novo lesions, in-stent restenosis, below knee disease, and femoropopliteal disease-so that value propositions are clearly supported by context-specific data. In parallel, optimize coating and delivery systems to enhance drug transfer efficiency and minimize downstream embolic risk, placing emphasis on both paclitaxel- and sirolimus-coated platforms depending on the clinical niche targeted.

Adopt a flexible supply chain strategy that balances localized manufacturing options with qualified multi-sourcing to mitigate tariff exposure and component scarcity. Commercially, tailor go-to-market models to end user requirements: design rapid onboarding and streamlined procedural kits for ambulatory surgical centers, create protocolized pathways and training modules for clinics performing outpatient interventions, and equip hospital teams with comprehensive health-economic narratives that address service-line and capital considerations. Leverage direct sales in high-value accounts where clinical partnership is critical, while using distributor relationships to accelerate penetration in fragmented or geographically dispersed markets.

Engage payers early with transparent evidence packages and real-world economic models that articulate long-term clinical and cost outcomes. Finally, invest in post-market surveillance, registry participation, and clinician education to reinforce safety profiles and to support incremental label expansion where clinical evidence permits. These combined measures will strengthen competitive positioning and enable scalable adoption across diverse clinical and regional contexts.

A transparent, mixed-methods research framework combining clinician interviews, technical assessments, and supply chain analysis to validate strategic insights

This research synthesis is grounded in a mixed-methods approach that triangulates multiple sources of evidence to ensure robustness and applicability. The methodology integrates targeted interviews with interventional cardiologists, vascular specialists, procurement leaders, and distribution partners to capture practitioner perspectives and procurement imperatives. These primary insights are complemented by a systematic review of peer-reviewed clinical literature, regulatory filings, and post-market surveillance reports to contextualize efficacy and safety signals across indications and drug chemistries.

Device design and manufacturing assessments draw on technical literature, patent landscapes, and expert consultations to evaluate coating technologies, excipient strategies, and catheter system innovations. Supply chain analysis was informed by discussions with manufacturers and logistic providers to map sourcing dependencies, tariff exposure, and manufacturing localization options. Commercial and reimbursement insights derived from interviews with hospital administrators, ambulatory surgical center managers, and payers provide pragmatic perspectives on procurement cycles, contracting preferences, and value argumentation.

Throughout the research, findings were validated via cross-checking among independent expert reviewers and through iterative reconciliation of primary and secondary sources. Where uncertainties or divergent viewpoints emerged, sensitivity analyses and scenario-based reasoning were applied to highlight risks and contingent strategies rather than to produce numerical forecasts. The methodology emphasizes transparency, reproducibility, and alignment with the needs of clinical, commercial, and investment stakeholders seeking an actionable understanding of the drug eluting balloon environment.

Concluding synthesis linking clinical innovation, evidence generation, and operational strategy as the foundation for sustainable adoption of drug eluting balloons

In conclusion, drug eluting balloons occupy a strategically important and evolving niche in vascular intervention, blending the potential for durable antiproliferative benefit with procedural simplicity that avoids permanent implants. Adoption will continue to be driven by innovation in coating chemistry and delivery systems, by rigorous clinical evidence addressing key lesion subtypes, and by practical commercial strategies that reflect the needs of diverse care settings. Tariff pressures and regional regulatory nuance add complexity to commercialization planning but also create impetus for supply chain resilience and localized manufacturing strategies.

Manufacturers and stakeholders who align technical differentiation with targeted clinical programs and who engage payers and procurement leaders early will be best positioned to capture long-term value. As the field advances, ongoing investment in transparent post-market surveillance and real-world evidence will be essential to sustaining clinician confidence and payer support. Ultimately, success in this market will depend on an integrated approach that marries scientific rigor with operational excellence and a clear focus on patient-centered outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of novel polymer-free drug coatings to reduce late adverse events in drug eluting balloon procedures
  • 5.2. Emergence of sirolimus-eluting balloon technology expanding treatment options for peripheral arterial disease patients
  • 5.3. Integration of intravascular imaging guidance systems with drug eluting balloon therapies for precision lesion assessment
  • 5.4. Strategic collaborations between medical device manufacturers and pharmaceutical companies for optimized drug formulations on balloons
  • 5.5. Growing investment in micro-poration technology to enhance local drug transfer efficiency during balloon angioplasty interventions
  • 5.6. Expanding focus on health economics and reimbursement strategies to improve market access for drug eluting balloon devices
  • 5.7. Rapid market growth in Asia-Pacific driven by rising incidence of peripheral artery disease and improved healthcare infrastructure

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Eluting Balloon Market, by Application

  • 8.1. Coronary Artery Disease
    • 8.1.1. De Novo Lesion
    • 8.1.2. In-Stent Restenosis
  • 8.2. Peripheral Artery Disease
    • 8.2.1. Below Knee
    • 8.2.2. Femoropopliteal

9. Drug Eluting Balloon Market, by Drug Type

  • 9.1. Paclitaxel-Coated
  • 9.2. Sirolimus-Coated

10. Drug Eluting Balloon Market, by End User

  • 10.1. Ambulatory Surgical Center
  • 10.2. Clinic
  • 10.3. Hospital

11. Drug Eluting Balloon Market, by Product Type

  • 11.1. Conventional Balloon
  • 11.2. Specialty Balloon

12. Drug Eluting Balloon Market, by Distribution Channel

  • 12.1. Direct
  • 12.2. Distributor

13. Drug Eluting Balloon Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Eluting Balloon Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Eluting Balloon Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Medtronic plc
    • 16.3.2. Boston Scientific Corporation
    • 16.3.3. B. Braun SE
    • 16.3.4. Koninklijke Philips N.V.
    • 16.3.5. Becton Dickinson and Company
    • 16.3.6. Terumo Corporation
    • 16.3.7. MicroPort Scientific Corporation
    • 16.3.8. Cook Medical LLC
    • 16.3.9. Elixir Medical Corporation
    • 16.3.10. Concept Medical Research Private Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DRUG ELUTING BALLOON MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DRUG ELUTING BALLOON MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG ELUTING BALLOON MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. GCC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GCC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GCC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. GCC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. GCC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 262. GCC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 263. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. GCC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. GCC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. G7 DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. G7 DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. G7 DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. G7 DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. G7 DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 310. G7 DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 311. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 312. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 313. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. G7 DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. G7 DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. NATO DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. NATO DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. NATO DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. NATO DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. NATO DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 326. NATO DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 327. NATO DRUG ELUTING BALLOON MARKET SIZE, BY PERI